TARA: Protara Therapeutics, Inc. Stock

by  •  • Comments Off on TARA: Protara Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 128.70
Enterprise Value ($M) -34.10
Book Value ($M) 167.13
Book Value / Share 4.87
Price / Book 0.77
NCAV ($M) 157.84
NCAV / Share 4.60
Price / NCAV 0.82

Profitability (mra)
Return on Invested Capital (ROIC) -0.26
Return on Assets (ROA) -0.56
Return on Equity (ROE) -0.65

Liquidity (mrq)
Quick Ratio 15.71
Current Ratio 15.71

Balance Sheet (mrq) ($M)
Current Assets 172.16
Assets 181.45
Liabilities 14.32
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -49.15
Net Income -44.60
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -35.81
Cash from Investing 19.16
Cash from Financing 139.87

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
5 days ago 13G/A Janus Henderson Group Plc 10.30 -30.48
02-14 13G/A Citadel Advisors Llc 4.70
02-14 13G/A Opaleye Management Inc. 5.32 8.56
02-14 13G/A Ra Capital Management, L.p. 9.90 65.54
02-14 13G/A Woodline Partners LP 3.90 -15.56
02-12 13G Adage Capital Management, L.P. 6.56
12-17 13G Velan Capital Investment Management LP 5.90
11-14 13G/A CVI Investments, Inc. 2.80 0.00
2024-02-14 13G/A Orbimed Advisors Llc 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-05 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURS
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PUR
2024-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-11 48,231 174,132 27.70
2025-03-10 52,747 155,980 33.82
2025-03-07 54,943 174,614 31.47
2025-03-06 124,172 499,632 24.85

(click for more detail)

Similar Companies
SPRY – ARS Pharmaceuticals, Inc. STRO – Sutro Biopharma, Inc.
SUPN – Supernus Pharmaceuticals, Inc. TBPH – Theravance Biopharma, Inc.
TCRX – TScan Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io